145 related articles for article (PubMed ID: 36098964)
1. Loss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis.
Zhu LY; Yuan JB; Zhang L; He CX; Lin X; Xu B; Jin GH
Cancer Res; 2022 Nov; 82(22):4153-4163. PubMed ID: 36098964
[TBL] [Abstract][Full Text] [Related]
2. Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
Yokoyama A; Cleary ML
Cancer Cell; 2008 Jul; 14(1):36-46. PubMed ID: 18598942
[TBL] [Abstract][Full Text] [Related]
3. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
[TBL] [Abstract][Full Text] [Related]
4. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
5. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
6. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
[TBL] [Abstract][Full Text] [Related]
7. Unlike Its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival.
Van Belle S; El Ashkar S; Čermáková K; Matthijssens F; Goossens S; Canella A; Hodges CH; Christ F; De Rijck J; Van Vlierberghe P; Veverka V; Debyser Z
Cells; 2021 Jan; 10(1):. PubMed ID: 33477970
[TBL] [Abstract][Full Text] [Related]
8. Involvement of Gpr125 in the myeloid sarcoma formation induced by cooperating MLL/AF10(OM-LZ) and oncogenic KRAS in a mouse bone marrow transplantation model.
Fu JF; Yen TH; Chen Y; Huang YJ; Hsu CL; Liang DC; Shih LY
Int J Cancer; 2013 Oct; 133(8):1792-802. PubMed ID: 23564351
[TBL] [Abstract][Full Text] [Related]
9. Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models.
Ono R; Masuya M; Inoue N; Shinmei M; Ishii S; Maegawa Y; Maharjan BD; Katayama N; Nosaka T
PLoS One; 2021; 16(3):e0248425. PubMed ID: 33705482
[TBL] [Abstract][Full Text] [Related]
10. A MENage à Trois in leukemia.
Roudaia L; Speck NA
Cancer Cell; 2008 Jul; 14(1):3-5. PubMed ID: 18598937
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic alterations contribute to promoter activity of imprinting gene IGF2.
Zheng QF; Xu B; Wang HM; Ding LH; Liu JY; Zhu LY; Qiu H; Zhang L; Ni GY; Ye J; Gao SB; Jin GH
Biochim Biophys Acta Gene Regul Mech; 2018 Feb; 1861(2):117-124. PubMed ID: 29413895
[TBL] [Abstract][Full Text] [Related]
12. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
14. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
[TBL] [Abstract][Full Text] [Related]
15. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
16. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
[TBL] [Abstract][Full Text] [Related]
17. A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
Soto-Feliciano YM; Sánchez-Rivera FJ; Perner F; Barrows DW; Kastenhuber ER; Ho YJ; Carroll T; Xiong Y; Anand D; Soshnev AA; Gates L; Beytagh MC; Cheon D; Gu S; Liu XS; Krivtsov AV; Meneses M; de Stanchina E; Stone RM; Armstrong SA; Lowe SW; Allis CD
Cancer Discov; 2023 Jan; 13(1):146-169. PubMed ID: 36264143
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
[TBL] [Abstract][Full Text] [Related]
19. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
20. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
Jin S; Zhao H; Yi Y; Nakata Y; Kalota A; Gewirtz AM
J Clin Invest; 2010 Feb; 120(2):593-606. PubMed ID: 20093773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
